Skip to content

Category: Company TechnologySyndicate content

Ben Franklin Technology Partners of Southeastern Pennsylvania Approves Investments for Nine Early-Stage Companies


Newly funded companies create medical innovations, help businesses improve productivity
PHILADELPHIA, PA (www.sep.benfranklin.org) – Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP/SEP) recently approved investments totaling $1,800,000 for nine early-stage Pennsylvania companies with promising technology innovations.  Included in this is a $500,000 investment in Molecular Detection Inc. (MDI).  MDI developed a quick method to detect drug resistant Staph infections.  Investment details follow.

Meet With... ALLOY Ventures

Thurs. September 9, 2010 (Application Deadline, August 13, 2010)

The EBC 2010 Meet with Series is featuring Alloy Ventures, an early-stage venture capital firm with over $1 billion under management that invests in the entrepreneurs creating the next generation of ground-breaking Information Technology, Life Sciences, and Cleantech companies. The Meet with Series is a partnering and coaching series for entrepreneurs. The goal of the program is to facilitate meetings between cleantech entrepreneurs and investors, customers and potential partners.

On September 9, 2010 Dan Rubin, General Partner at Alloy Ventures will present on what they are looking for in a portfolio company, how best to work with them and their investment process. After the presentation and Q&A, each pre-approved attendee will be granted a one-on-one meeting. Meetings are subject to approval.

It is FREE to apply. Please send your Executive Summary by August 13, 2010 to jovan@prescienceintl.com. The Review Board, composed of the EBC management team, sponsors, partners and mentors, will then meet to consider your application. 
Click here to read more about this event»

Venue
Presentations and one-on-one meetings will take place On Sept. 9, 2010 at Fenwick & West
Fenwick & West LLP
801 California Street
Mountain View, CA 94041 

 

Massachusetts Life Sciences Center Provides $50,000 Grant to Support Life Sciences Collaborative’s Biomanufacturing Initiative

 

 


At two-year mark, state’s Life Sciences Initiative provides strong return on investment

Waltham, MA – The Massachusetts Life Sciences Center is providing a $50,000 grant to the Massachusetts Life Sciences Collaborative to support an initiative aimed at strengthening the state’s biomanufacturing sector through a Massachusetts Biomanufacturing Roundtable and the development of a comprehensive Biomanufacturing action agenda during the 2010 calendar year.  The Biomanufacturing Roundtable includes participation from influential life sciences, biomanufacturing, academic, and government leaders, including Massachusetts Life Sciences Center President & CEO, Dr. Susan Windham-Bannister.  The Roundtable is co-chaired by Taligen Therapeutics CEO Abbie Celniker, Acceleron Pharma Senior Vice President of Manufacturing Bob Steininger, and former Pfizer Vice President Mickey Koplove.

Governor Patrick and Life Sciences Leaders Urge Massachusetts Companies to Apply To Federal Therapeutic Tax Credit Program

 

 

Application period opens on June 21st
 
Contact:  Angus G. McQuilken, MLSC VP for Communications
Phone: (617) 921-7749   Email: amcquilken@masslifesciences.com

Boston, MA – Governor Patrick, the Massachusetts Life Sciences Center, MassBio and MassMEDIC today urged qualifying companies to apply for the Therapeutic Discovery Tax Credit, a new federal program created under the Affordable Care Act to support biomedical research.  Qualifying companies may apply to the new federal program starting on Monday, June 21, 2010 with applications due by July 21, 2010.  Applicants will receive a determination no later than October 29, 2010.  More information is available on the web site of the Massachusetts Life Sciences Center, www.masslifescience.com.

Massachusetts Life Sciences Center Announces 2010 Small Business Matching Grant (SBMG) Program Awards

 

Center Awards $1.5 million to foster job growth and technology commercialization in the Massachusetts Life Sciences Supercluster

For Immediate Release:                                 Date:  May 28, 2010

Contact:  Angus G. McQuilken, MLSC VP for Communications

Phone: (617) 921-7749   Email: amcquilken@masslifesciences.com

“This is all about jobs. By helping life sciences companies grow, we create new opportunities for people to work,” said Governor Deval Patrick. “As we continue to strengthen our global leadership in the life sciences, this program will meet an important need and make Massachusetts an even more attractive place for life sciences companies to locate and grow.”

Waltham, MA – The Massachusetts Life Sciences Center’s Board of Directors today awarded $1.5 million in Small Business Matching Grants to three life sciences companies in Massachusetts.  The companies receiving grants are Boston Biochem Inc. and Tetragenetics Inc., both of Cambridge and Thermedical Inc. of Somerville.   Each company will receive $500,000 from the Center to match federal small business grant funding that the companies had previously been awarded.  The grants represent the first round of awards issued under the Center’s Small Business Matching Grant (SBMG) Program.  The three companies that are receiving awards have committed to collectively creating 40 new jobs in the Commonwealth by the end of 2011, including six jobs to be relocated from New York.

The Center’s Small Business Matching Grant Program, launched in January 2010 as part of the state’s ten-year, $1 billion Life Sciences Initiative, will match federal small business grant funding for early-stage life sciences companies engaged in life sciences research and development, commercialization and manufacturing in Massachusetts. Goals of the program include the creation of jobs in Massachusetts by the commercialization of products with high potential for market adoption and penetration.

Governor Patrick, Massachusetts Life Sciences Center Leaders Visit Gateway Park in Worcester

 

 

FOR IMMEDIATE RELEASE     CONTACT    Juan Martinez
Tuesday, May 25, 2010                         Kim Haberlin
                                                      Heather Johnson
                                                      Caitlin Coyle
                                                      617-725-4025
 

Discuss area job growth under state's ten-year, $1 billion Life Sciences Initiative. 64% of dollars invested thus far have been in Central Massachusetts

WORCESTER – Tuesday, May 25, 2010 - Governor Deval Patrick and Susan Windham-Bannister, President & CEO of the Massachusetts Life Sciences Center, visited Worcester Polytechnic Institute's (WPI) Gateway Park today for a discussion of life sciences job growth in the park and the region. WPI recently received approval for a $6.6 million grant from the Center for Phase II construction at Gateway Park. The Governor met with leaders from WPI, the Massachusetts Academy of Math and Sciences, and Massachusetts Biomedical Initiatives (MBI), all of whom have benefitted from the Center's investment. The Governor also met employees of the companies and organizations located in the park, including employees of RXi Pharmaceuticals, a company that is participating in a cooperative research project with UMass Medical School (UMMS) that is funded through the Center's Cooperative Research Matching Grant Program. Both grants were made under the Patrick-Murray Administration's 10-year, $1 billion Life Sciences Initiative.

MSM Protein Technologies Announces the Appointment of Dr. Christopher Hentschel to the Board of Directors

Davis Farmer, Chairman of the Board of MSM Protein Technologies today announced that Chris Hentschel, Ph.D., has joined the Company's Board of Directors.  Dr. Hentschel has served as the President and CEO of Malaria  Medical Venture for the past ten years.  
 
MMV is a not-for-profit entity based in Geneva, Switzerland that discovers, develops and delivers new and affordable therapies for malaria and assures access to those most at risk from this disease.  Prior to joining MMV, Chris served as Chief Scientific Officer at Centocor where he oversaw research into a number of the products that J&J has brought to the market in recent years.  He also served as the founding head of the Collaborative Centre of the UK Medical Research Council in London, a pioneering technology transfer facility designed to promote collaborations between the MRC and industry.  He received his Ph.D . from King's College London, with a subsequent research fellowship from the European Molecular Biology Organization and NIH.

"Chris is a great addition to our board,” said Farmer..  “He is our first outside Director and as such will provide a valuable perspective to our decision making.  He is a true visionary with a great network of relationships in the pharmaceutical, academic and finance community.  He has a great track record for innovation and for the creation of successful industry collaborations.  We will look to him for guidance on many fronts including strategic decisions regarding the company's long term direction." 

Ben Franklin Technology Partners of Southeastern Pennsylvania Approves Investments for Eight Early-Stage Companies

Newly funded companies will create jobs, help businesses improve productivity, and more

PHILADELPHIA, PA (www.sep.benfranklin.org) – Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP/SEP) recently approved investments totaling $2,026,000 for eight early-stage Pennsylvania companies with promising technology innovations.

“This latest round of investments demonstrates the strength of our region’s energy sector and the continued commitment of our business solutions entrepreneurs,” said RoseAnn B. Rosenthal, President & CEO of Ben Franklin Technology Partners of Southeastern Pennsylvania.

New York-Based NeoStem, Inc. Officially Launches R&D Facility in Cambridge

 

Massachusetts Lieutenant Governor Timothy Murray joins life sciences leaders for ribbon-cutting ceremony 

Report from the trenches: starting, funding, and growing a life sciences business in today's economy

Report from the trenches: starting, funding, and growing a life sciences
business in today's economy
qed@qb3 UCSF
Thursday, April 1, 2010
12:00 to 1:00 pm
Byers Hall Room 212

 

Starting a business in any environment is a difficult proposition.
However, since the economic collapse of 2008 it's gotten even tougher. This session will explore some of the themes that are common to starting any life sciences company, and will look specifically at the current climate and what you can do to put yourself in the best position for success.

Speaker


Jeff Jensen is the CEO of Fluxion Biosciences, a functional cell analysis tools company and the very first tenant of the QB3 Garage. Jeff joined Fluxion in fall 2006, and has led the company through initial angel financing, a VC round, and subsequent commercialization of two product lines that are now marketed globally to academic and pharma/biotech labs. During his career Jeff has been involved in starting, guiding, and growing a number of life sciences companies, including Eksigent Technologies (drug discovery tools and medical devices), Nodality (molecular diagnostics), and Silicon Kinetics (life science tools). Jeff has a B.S. in chemical engineering from Cornell, and is a graduate of the Program for Management Development at Harvard Business School.

Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=201422

http://qb3.org/services/qed-qb3/?searchterm=qed

AdaptiveThemes